TFBS Bioscience, Inc.(TW:6939)
NT$19.40+1.20 (+6.89%)
TW:6939
TFBS Bioscience, Inc. financials statements
NT$19.40
At close:+1.20 (+6.89%)
TFBS Bioscience, Inc. (6939) Ratios
TFBS Bioscience, Inc. Ratios
TW:6939's free cash flow for Q2 2026 was NT$-19.02M. For the 2026 fiscal year, TW:6939's free cash flow was decreased by NT$-16.01M and operating cash flow was NT$-3.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.61 | 4.11 | 12.64 | 10.72 | 6.11 |
| Quick Ratio | 2.54 | 4.04 | 12.54 | 10.67 | 6.00 |
| Cash Ratio | 1.53 | 2.73 | 10.95 | 9.41 | 4.77 |
| Solvency Ratio | -0.08 | 0.04 | 0.34 | 0.51 | 0.48 |
| Operating Cash Flow Ratio | -0.05 | 0.15 | 0.43 | 0.76 | 0.42 |
| Short-Term Operating Cash Flow Coverage | -0.10 | 0.32 | 0.00 | 0.00 | 76.16 |
| Net Current Asset Value | NT$ 228.36M | NT$ 511.14M | NT$ 885.41M | NT$ 987.01M | NT$ 242.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.13 | 0.09 | 0.04 | 0.04 |
| Debt-to-Equity Ratio | 0.19 | 0.16 | 0.10 | 0.04 | 0.05 |
| Debt-to-Capital Ratio | 0.16 | 0.14 | 0.09 | 0.04 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.25 | 1.22 | 1.15 | 1.10 | 1.16 |
| Debt Service Coverage Ratio | -0.19 | 0.14 | 106.79 | 100.95 | 54.76 |
| Interest Coverage Ratio | -27.74 | -72.81 | -9.06 | 52.19 | 19.63 |
| Debt to Market Cap | 0.13 | 0.11 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 6.52 | 6.88 | 3.78 | 1.84 | 1.67 |
| Net Debt to EBITDA | 4.27 | -142.94 | -12.43 | -13.53 | -6.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 19.06% | 20.78% | 27.30% | 41.17% | 33.59% |
| EBIT Margin | -36.83% | -26.66% | 2.32% | 12.41% | 4.55% |
| EBITDA Margin | -9.97% | 1.24% | 27.66% | 27.04% | 20.36% |
| Operating Profit Margin | -40.39% | -33.91% | -2.35% | 13.36% | 3.73% |
| Pretax Profit Margin | -38.28% | -27.12% | 2.06% | 12.15% | 4.36% |
| Net Profit Margin | -38.58% | -21.42% | 2.12% | 10.96% | 3.81% |
| Continuous Operations Profit Margin | -38.58% | -21.42% | 2.12% | 10.96% | 3.81% |
| Net Income Per EBT | 100.78% | 78.97% | 102.83% | 90.18% | 87.36% |
| EBT Per EBIT | 94.80% | 79.97% | -87.56% | 90.94% | 116.68% |
| Return on Assets (ROA) | -5.11% | -2.58% | 0.34% | 2.03% | 1.25% |
| Return on Equity (ROE) | -6.40% | -3.14% | 0.39% | 2.24% | 1.44% |
| Return on Capital Employed (ROCE) | -6.20% | -4.68% | -0.40% | 2.68% | 1.36% |
| Return on Invested Capital (ROIC) | -5.61% | -3.38% | -0.39% | 2.36% | 1.18% |
| Return on Tangible Assets | -5.18% | -2.62% | 0.34% | 2.07% | 1.33% |
| Earnings Yield | -9.97% | -4.75% | 0.31% | 1.55% | 0.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.55 | 3.66 | 2.87 | 3.17 | 2.65 |
| Payables Turnover | 19.58 | 15.06 | 19.37 | 13.30 | 6.89 |
| Inventory Turnover | 11.24 | 11.11 | 19.07 | 26.12 | 18.23 |
| Fixed Asset Turnover | 0.22 | 0.27 | 0.69 | 1.19 | 1.07 |
| Asset Turnover | 0.13 | 0.12 | 0.16 | 0.19 | 0.33 |
| Working Capital Turnover Ratio | 0.42 | 0.23 | 0.23 | 0.40 | 0.96 |
| Cash Conversion Cycle | 94.03 | 108.30 | 127.45 | 101.79 | 104.88 |
| Days of Sales Outstanding | 80.19 | 99.68 | 127.15 | 115.26 | 137.88 |
| Days of Inventory Outstanding | 32.47 | 32.86 | 19.14 | 13.98 | 20.02 |
| Days of Payables Outstanding | 18.64 | 24.24 | 18.85 | 27.45 | 53.01 |
| Operating Cycle | 112.66 | 132.54 | 146.30 | 129.23 | 157.89 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.28 | 1.01 | 1.04 | 2.75 | 1.62 |
| Free Cash Flow Per Share | -6.73 | -12.01 | -0.55 | 1.01 | 0.15 |
| Dividend Paid and CapEx Coverage Ratio | -0.04 | 0.08 | 0.62 | 1.58 | 1.10 |
| Capital Expenditure Coverage Ratio | -0.04 | 0.08 | 0.65 | 1.58 | 1.10 |
| Operating Cash Flow Coverage Ratio | -0.04 | 0.15 | 0.28 | 1.51 | 0.98 |
| Operating Cash Flow to Sales Ratio | -0.05 | 0.16 | 0.16 | 0.31 | 0.13 |
| Free Cash Flow Yield | -31.45% | -42.27% | -1.21% | 1.61% | 0.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.05 | -21.04 | 325.71 | 64.43 | 132.98 |
| Price-to-Sales (P/S) Ratio | 3.87 | 4.51 | 6.89 | 7.09 | 5.04 |
| Price-to-Book (P/B) Ratio | 0.64 | 0.66 | 1.27 | 1.45 | 1.91 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.18 | -2.37 | -82.61 | 61.99 | 409.03 |
| Price-to-Operating Cash Flow Ratio | -76.76 | 28.23 | 43.78 | 22.75 | 38.55 |
| Price-to-Earnings Growth (PEG) Ratio | -0.17 | 0.02 | -3.81 | 0.61 | 0.02 |
| Enterprise Value Multiple | -34.56 | 220.80 | 12.49 | 12.68 | 18.03 |
| Enterprise Value | 665.41M | 493.93M | 801.36M | 866.44M | 590.73M |
| EV to EBITDA | -34.56 | 220.80 | 12.49 | 12.68 | 18.03 |
| EV to Sales | 3.45 | 2.74 | 3.46 | 3.43 | 3.67 |
| EV to Free Cash Flow | -2.83 | -1.44 | -41.40 | 29.99 | 298.20 |
| EV to Operating Cash Flow | -68.31 | 17.14 | 21.94 | 11.01 | 28.10 |
| Tangible Book Value Per Share | 32.77 | 42.25 | 35.24 | 42.21 | 30.41 |
| Shareholders’ Equity Per Share | 33.32 | 43.03 | 35.95 | 43.18 | 32.77 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.21 | -0.03 | 0.10 | 0.13 |
| Revenue Per Share | 5.53 | 6.30 | 6.61 | 8.82 | 12.41 |
| Net Income Per Share | -2.13 | -1.35 | 0.14 | 0.97 | 0.47 |
| Tax Burden | 1.01 | 0.79 | 1.03 | 0.90 | 0.87 |
| Interest Burden | 1.04 | 1.02 | 0.89 | 0.98 | 0.96 |
| Research & Development to Revenue | 0.34 | 0.25 | 0.16 | 0.13 | 0.16 |
| SG&A to Revenue | 0.26 | 0.29 | 0.20 | 0.14 | 0.14 |
| Stock-Based Compensation to Revenue | 0.02 | 0.06 | 0.06 | 0.03 | 0.01 |
| Income Quality | 0.13 | -0.59 | 7.65 | 2.56 | 3.00 |
Currency in TWD
